Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellenis is a proprietary autologous platelet-rich plasma (PRP) preparation system used to concentrate platelets from a patient's own peripheral blood for regenerative medical applications. The system utilizes a specialized separation gel and centrifugation process to isolate a high concentration of viable platelets while significantly reducing the presence of red blood cells and pro-inflammatory granulocytes. Once prepared and injected into target tissues, the concentrated platelets undergo activation and degranulation, releasing a suite of essential growth factors including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF). These factors bind to specific cellular receptors to stimulate angiogenesis, fibroblast proliferation, and collagen synthesis. Cellenis is primarily indicated for aesthetic procedures, such as skin rejuvenation and hair restoration, as well as for orthopedic conditions including joint pain and soft tissue injuries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cellenis.